METODO IN VITRO E KIT PER PREDIRE L’ANDAMENTO CLINICO E LA SENSIBILITA’ AI FARMACI NEI PAZIENTI CON NEFROPATIA MEMBRANOSA

摘要

The present invention relates to an in vitro method for the prediction of the clinical outcome in terms of proteinuria and renal function of patients with Membranous Nephropathy. Prediction of such an outcome can be done by determining the levels in serum of anti-SOD 2 and/or anti-apha enolase IgG4 at the time of diagnosis of the renal lesion and before starting any therapy. An in vitro method for monitoring a therapy against membranous nephropathy in subjects affected by the disease that can be done by determining serum levels of anti-SOD2 and/or anti-alpha enolase IgG4 at the start and before the therapy and during the follow up. Positivity of one of the antibodies above recognizes among patients positive to anti-PLA2r epitopes the 100% of patients in which proteinuria will not remit after 12 months of therapies. This finding has an addictive and crucial potential for defining patients who can be treated.